• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Laurent Bonello, Udaya S. Tantry, +18 authors Paul A Gurbel
  • Medicine
  • Journal of the American College of Cardiology
  • 2010 (First Publication: 1 September 2010)
  • The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplateletContinue Reading
  • Jessica L. Mega, Tabassome Simon, +18 authors Marc S Sabatine
  • Medicine
  • JAMA
  • 2010 (First Publication: 27 October 2010)
  • CONTENT Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, butContinue Reading
  • Udaya S. Tantry, Laurent Bonello, +20 authors Paul A Gurbel
  • Medicine
  • Journal of the American College of Cardiology
  • 2013 (First Publication: 1 December 2013)
  • Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronaryContinue Reading
  • Paul A Gurbel, Kevin P. Bliden, +5 authors Udaya S. Tantry
  • Medicine
  • Journal of the American College of Cardiology
  • 2005 (First Publication: 1 November 2005)
  • OBJECTIVES We investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and high thrombin-induced clot strength to postdischarge ischemic events in patients undergoingContinue Reading
  • Paul A Gurbel, Kevin P. Bliden, +13 authors Robert F Storey
  • Medicine
  • Circulation
  • 2009 (First Publication: 18 November 2009)
  • BACKGROUND Ticagrelor is the first reversibly binding oral P2Y(12) receptor antagonist. This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using theContinue Reading
  • Udaya S. Tantry, Kevin P. Bliden, Paul A Gurbel
  • Medicine
  • Journal of the American College of Cardiology
  • 2005 (First Publication: 1 November 2005)
  • OBJECTIVES This study sought to determine the prevalence of platelet aspirin resistance using methods that directly indicate the degree of platelet cyclooxygenase inhibition. BACKGROUND AspirinContinue Reading
  • Paul A Gurbel, Kevin P. Bliden, +7 authors Udaya S. Tantry
  • Medicine
  • Circulation
  • 2007 (First Publication: 29 January 2008)
  • BACKGROUND The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1 inhibition. Controversy exists on the prevalence of platelet resistance to aspirin in patients with coronaryContinue Reading